Patent ID: 6670387
Filing Date: 2003-12-30
Classification: A61K,A61P,C07D

Abstract:
A method of treating of thrombocytopenia in a mammal in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Formula (II) wherein:R, R1, R2, R3, R4 and R5 are each independently selected from hydrogen, â€”C(O)OR6, â€”CONR9R10, â€”SO2NR9R10, phosphonic acid, phosphinic acid, C1-6alkyl, C1-6alkoxy, â€”(CH2)pOR6, nitro, cyano, halogen, â€”NR9R10, N-acylamino, N-sulfonylamino, â€”S(O)nR6, C5-C12aryl, substituted C5-C12aryl, alkyl, cycloalkyl, substituted cycloalkyl, protected â€”OH, and alkyl substituted with one or more substituents selected from the group consisting of alkoxy, acyloxy, C5-C12aryl, substituted C5-C12aryl, â€”NR9R10, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, â€”C(O)OR6, â€”C(O)NR9R10, â€”S(O)2NR9R10, â€”S(O)nR6, aryloxy, nitro, cyano, halogen, and protected â€”OH; where n is 0 to 3; p is 0-6; R6 is selected from hydrogen, alkyl, cycloalkyl, C6-C12aryl, substituted alkyl, substituted cycloalkyl and substituted C6-C12aryl, and R9 and R10 are independently selected from hydrogen, cycloalkyl, C6-C12aryl, substituted cycloalkyl, substituted C6-C12aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of alkoxy, acyloxy, aryloxy, â€”NR6R6, N-acylamino, oxo, hydroxy, â€”C(O)OR6, â€”S(O)nR6, â€”C(O)NR6R6, â€”S(O)2NR6R6, nitro, cyano, halogen, cycloalkyl, substituted cycloalkyl, C5-C12aryl, substituted C5-C12aryl and protected â€”OH where n and R6 are as described above; or R9 and R10 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen; m is 0-6; and AR is selected from the group consisting of naphthalene, phenyl, pyrazole and phenanthrene; each of which is optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, substituted cycloalkyl, C5-C12aryl, substituted C5-C12aryl, aryloxy, hydroxy, alkoxy, acyloxy, â€”NR7R8, N-acylamino, N-sulfonylamino, nitro, cyano, halogen, â€”C(O)OR6, â€”C(O)NR7R8, â€”S(O)2NR7R8, â€”S(O)nR6, protected â€”OH, and alkyl substituted with one or more substituents selected from the group consisting of alkoxy, acyloxy, C5-C12aryl, substituted C5-C12aryl, â€”NR6R6, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, â€”C(O)OR6, â€”C(O)NR7R8, â€”S(O)2NR7R8, â€”S(O)nR6, aryloxy, nitro, cyano, halogen, and protected â€”OH; where n is 0 to 3; R6 is selected from hydrogen, alkyl, cycloalkyl, C6-C12aryl, substituted alkyl, substituted cycloalkyl and substituted C6-C12aryl; and R7 and R8 are independently hydrogen, cycloalkyl, C6-C12aryl, substituted cycloalkyl, substituted C6-C12aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of alkoxy, acyloxy, aryloxy, â€”NR6R6, N-acylamino, oxo, hydroxy, â€”C(O)OR6, â€”S(O)nR6, â€”C(O)NR6R6, â€”S(O)2NR6R6, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, C6-C12aryl, substituted C6-C12aryl and protected â€”OH where n and R6 are as described above; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.